Tim Anderson
Stock Analyst at B of A Securities
(2.57)
# 2,184
Out of 5,241 analysts
51
Total ratings
50%
Success rate
3.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $68 → $67 | $57.31 | +16.91% | 3 | Apr 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $228.92 | -3.46% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $988.09 | +28.33% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $112.56 | +6.61% | 5 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $629.68 | -0.43% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $25.33 | +18.44% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $324.39 | -16.15% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $78.75 | +10.48% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $4.36 | +473.39% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $209.41 | -2.58% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $129.67 | -2.83% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $48.11 | -29.33% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $191.91 | -7.25% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $149.15 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $183.92 | - | 1 | Sep 22, 2017 |
Bristol-Myers Squibb Company
Apr 9, 2026
Maintains: Buy
Price Target: $68 → $67
Current: $57.31
Upside: +16.91%
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $228.92
Upside: -3.46%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $988.09
Upside: +28.33%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $112.56
Upside: +6.61%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $629.68
Upside: -0.43%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $25.33
Upside: +18.44%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $324.39
Upside: -16.15%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $78.75
Upside: +10.48%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $4.36
Upside: +473.39%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $209.41
Upside: -2.58%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $129.67
Upside: -2.83%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $48.11
Upside: -29.33%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $191.91
Upside: -7.25%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $149.15
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $183.92
Upside: -